Wintermeyer S M, Nahata M C, Kyllonen K S
Ohio State University, Columbus.
Ann Pharmacother. 1994 Jul-Aug;28(7-8):925-39. doi: 10.1177/106002809402800718.
To provide a review of pertussis vaccines, including information on efficacy, adverse reactions, and antibody production following administration of both whole-cell and acellular pertussis vaccines.
A MEDLINE search and extensive review of journals was conducted to identify the information for this review.
Pertinent studies reporting experience with pertussis vaccinations were reviewed.
The differences in efficacy, adverse reactions, and antibody responses between whole-cell and acellular pertussis vaccines are emphasized. The status of acellular pertussis vaccination in the US is defined.
Acellular (chemically detoxified or recombinant) pertussis vaccine formulation appears to cause fewer adverse reactions than whole-cell vaccine in most studies. Clinical efficacy and safety in the very young has not been well established. Thus, acellular pertussis vaccine is reserved for the 4th and 5th doses in the US. Oral or intranasal formulations of the pertussis vaccine are being evaluated.
综述百日咳疫苗，包括全细胞百日咳疫苗和无细胞百日咳疫苗接种后的疗效、不良反应及抗体产生情况的信息。
进行了MEDLINE检索并广泛查阅期刊以获取本综述所需信息。
对报告百日咳疫苗接种经验的相关研究进行了综述。
强调了全细胞百日咳疫苗和无细胞百日咳疫苗在疗效、不良反应及抗体反应方面的差异。明确了美国无细胞百日咳疫苗的接种现状。
在大多数研究中，无细胞（化学解毒或重组）百日咳疫苗配方似乎比全细胞疫苗引起的不良反应更少。在婴幼儿中的临床疗效和安全性尚未得到充分证实。因此，在美国无细胞百日咳疫苗仅用于第4剂和第5剂接种。正在评估百日咳疫苗的口服或鼻内给药制剂。
